• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far.波生坦与口服抗凝剂在HIV患者中的应用:从目前报告的病例中我们能学到什么。
Hematol Rep. 2011 Aug 31;3(2):e16. doi: 10.4081/hr.2011.e16. Epub 2011 Oct 10.
2
Bosentan and warfarin interaction.波生坦与华法林的相互作用。
Ann Pharmacother. 2003 Jul-Aug;37(7-8):1028-31. doi: 10.1345/aph.1C398.
3
Warfarin and bosentan interaction in a patient with pulmonary hypertension secondary to bilateral pulmonary emboli.华法林和波生坦在一位因双侧肺栓塞导致肺动脉高压的患者中的相互作用。
Clin Ther. 2010 Jan;32(1):53-6. doi: 10.1016/j.clinthera.2010.01.004.
4
Interaction of acenocoumarol and sitaxentan in pulmonary arterial hypertension.醋硝香豆素与西他生坦在肺动脉高压中的相互作用。
Eur J Clin Invest. 2009 Jun;39 Suppl 2:14-8. doi: 10.1111/j.1365-2362.2009.02116.x.
5
Outpatient management of oral anticoagulation therapy in patients with nonvalvular atrial fibrillation.非瓣膜性心房颤动患者口服抗凝治疗的门诊管理。
Bosn J Basic Med Sci. 2009 Nov;9(4):313-9. doi: 10.17305/bjbms.2009.2787.
6
Better stability of acenocoumarol compared to warfarin treatment in one-year observational, clinical study in patients with nonvalvular atrial fibrillation.在一项针对非瓣膜性心房颤动患者的为期一年的观察性临床研究中,与华法林治疗相比,醋硝香豆素具有更好的稳定性。
Med Glas (Zenica). 2011 Feb;8(1):9-14.
7
Potential interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and role of CYP2C9 genotype.醋硝香豆素与双氯芬酸、萘普生和布洛芬之间的潜在相互作用及CYP2C9基因分型的作用
Thromb Haemost. 2004 Jan;91(1):95-101. doi: 10.1160/TH03-05-0325.
8
Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial.阿哌沙班药效学剂量算法与常规护理在静脉血栓栓塞性疾病患者启动口服抗凝治疗中的应用效率和效果比较:一项随机对照试验研究方案。
Trials. 2012 Dec 13;13:239. doi: 10.1186/1745-6215-13-239.
9
A placebo-controlled study of interaction between nabumetone and acenocoumarol.一项关于萘丁美酮与醋硝香豆素相互作用的安慰剂对照研究。
Br J Clin Pharmacol. 1999 Apr;47(4):441-4. doi: 10.1046/j.1365-2125.1999.00916.x.
10
[Comparison of quality and hemorragic risk of oral anticoagulant therapy using acenocoumarol versus warfarin].使用醋硝香豆素与华法林进行口服抗凝治疗的质量及出血风险比较
Med Clin (Barc). 2008 Jun 21;131(3):96-7. doi: 10.1157/13124012.

本文引用的文献

1
Pharmacogenetics of anticoagulants.抗凝剂的药物遗传学
Hum Genomics Proteomics. 2010 Sep 13;2010:754919. doi: 10.4061/2010/754919.
2
Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes.评价内皮素受体拮抗剂安贝生坦、达鲁生坦、波生坦和西他生坦作为人肝细胞三明治培养物中肝胆转运体的底物和抑制剂。
Can J Physiol Pharmacol. 2010 Jun;88(6):682-91. doi: 10.1139/Y10-060.
3
Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants.波生坦与洛匹那韦/利托那韦在健康受试者中的相互药代动力学相互作用。
Antivir Ther. 2010;15(2):157-63. doi: 10.3851/IMP1506.
4
Warfarin and bosentan interaction in a patient with pulmonary hypertension secondary to bilateral pulmonary emboli.华法林和波生坦在一位因双侧肺栓塞导致肺动脉高压的患者中的相互作用。
Clin Ther. 2010 Jan;32(1):53-6. doi: 10.1016/j.clinthera.2010.01.004.
5
Proposal for a new tool to evaluate drug interaction cases.关于评估药物相互作用病例的新工具的提议。
Ann Pharmacother. 2007 Apr;41(4):674-80. doi: 10.1345/aph.1H423. Epub 2007 Mar 27.
6
In silico pharmacogenetics of warfarin metabolism.华法林代谢的计算机药物遗传学
Nat Biotechnol. 2006 May;24(5):531-6. doi: 10.1038/nbt1195.
7
Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.洛匹那韦/利托那韦可诱导细胞色素P450酶CYP2C9、CYP2C19和CYP1A2的肝脏活性,但在健康志愿者中,通过表型药物鸡尾酒检测发现,它会抑制CYP3A的肝脏和肠道活性。
J Acquir Immune Defic Syndr. 2006 May;42(1):52-60. doi: 10.1097/01.qai.0000219774.20174.64.
8
Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.双重内皮素受体拮抗剂波生坦的临床药理学
Clin Pharmacokinet. 2004;43(15):1089-115. doi: 10.2165/00003088-200443150-00003.
9
Bosentan and warfarin interaction.波生坦与华法林的相互作用。
Ann Pharmacother. 2003 Jul-Aug;37(7-8):1028-31. doi: 10.1345/aph.1C398.
10
Severe interaction between ritonavir and acenocoumarol.
Ann Pharmacother. 2002 Apr;36(4):621-3. doi: 10.1345/aph.19361.

波生坦与口服抗凝剂在HIV患者中的应用:从目前报告的病例中我们能学到什么。

Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far.

作者信息

Morales-Molina José Antonio, Martínez-de la Plata Juan Enrique, Urquízar-Rodríguez Olivia, Molina-Arrebola María Angustias

机构信息

Pharmacy Department and.

出版信息

Hematol Rep. 2011 Aug 31;3(2):e16. doi: 10.4081/hr.2011.e16. Epub 2011 Oct 10.

DOI:10.4081/hr.2011.e16
PMID:22184537
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3238480/
Abstract

Pulmonary arterial hypertension is an infrequent but nevertheless serious life-threatening severe complication of HIV infection. It can be treated with bosentan and oral anticoagulants. Bosentan could induce the acenocoumarol metabolism and it increases the INR values. Until now, no study of interaction between bosentan and oral anticoagulants in HIV patients has reported. So we present a case of this interaction between these drugs and we reviewed MEDLINE to identify all the papers published so far. In our case, several weeks after increasing dose of bosentan acenocoumarol dose had to be progressively increased to 70 mg/week (+33%) without obtaining an adequate INR level (2.0-3.0). Forty-nine days later, we achieved a therapeutic INR with 90 mg/week of warfarin. The use of bosentan and oral anticoagulants together in these patients require a closer monitoring during first weeks of treatment, after increasing the bosentan dose and even during longer periods of time.

摘要

肺动脉高压是一种在HIV感染中不常见但却严重危及生命的严重并发症。它可用波生坦和口服抗凝剂治疗。波生坦可诱导醋硝香豆素的代谢并增加国际标准化比值(INR)值。迄今为止,尚未有关于HIV患者中波生坦与口服抗凝剂之间相互作用的研究报道。因此,我们呈现了这样一个药物间相互作用的病例,并查阅了医学文献数据库(MEDLINE)以识别迄今发表的所有论文。在我们的病例中,增加波生坦剂量数周后,醋硝香豆素的剂量不得不逐渐增加至70毫克/周(增加了33%),但仍未获得足够的INR水平(2.0 - 3.0)。49天后,我们使用90毫克/周的华法林达到了治疗性INR。在这些患者中联合使用波生坦和口服抗凝剂时,在治疗的最初几周、增加波生坦剂量后甚至更长时间段内都需要更密切的监测。